NR-18290??Mycobacterium tuberculosis, CDC1551, Transposon Mutant 1942 (MT0618, Rv0589)(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant 1942 (MT0618, Rv0589)|2°C to 8°C|NIH - TB Vaccine Testing and Research Materials ContractAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant 1942 (MT0618, Rv0589), NR-18290."|
Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
At this time, BEI Resources only maintains seed stock of this item. Once a request is received for this item, it will be added to our production queue. Please allow ample time for distribution lots to be made available.
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized. M. tuberculosis, transposon mutant 1942 was created by disruption of an MCE-family protein (MT0618, Rv0589) of the wild-type strain CDC1551.
Each tube contains a Lowenstein-Jensen (LJ) agar slant that was inoculated with 0.1 mL of bacterial culture and incubated 2 to 6 weeks at 37°C.
TARGET: Rv0589MT Number (JCVI): MT0618Tuberculist: Rv0589ORF Description: MCE-family proteinORF Size: 1215POI: 868
Additional information is available at Mycobacterium tuberculosis CDC1551 Transposon Mutant Library.
This mutant was developed by Lamichhane, et al. at the Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, PubMed: 12775759.